Serum CXCL16: A new predictor of liver inflammation in patients with chronic hepatitis B
Open Access
- 25 December 2023
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (2) , 107-119
Abstract
The prompt initiation of antiviral therapy is essential in patients with chronic hepatitis B (CHB), especially when severe liver inflammation is detected. However, transcutaneous liver puncture, the gold standard for assessing liver inflammation, is invasive and its widespread application is limited. Therefore, there is an urgent need for more non‐invasive markers to predict liver inflammation. In our retrospective cross‐sectional study, which included 120 CHB patients and 31 healthy subjects, we observed a significant increase in serum chemokine C‐X‐C‐motif ligand 16 (CXCL16) in CHB patients compared to healthy controls (p < .001). Notably, patients with severe inflammation (Scheuer's grade G ≥ 3, n = 26) exhibited a substantial increase in serum CXCL16 compared to those with non‐severe inflammation (Scheuer's grade G < 3, n = 96) [(median, IQR), 0.42 (0.24–0.71) ng/mL vs. 1.01 (0.25–2.09) ng/mL, p < .001]. Furthermore, we developed a predictive model that combined CXCL16 with platelet count (PLT), alanine aminotransferase (ALT) and albumin (ALB) to accurately predict liver inflammation in CHB patients. This model was more effective than ALT alone in predicting liver inflammation (AUC, 0.92 vs. 0.81, p = .015). Additionally, using an HBV‐transduced mouse model, we demonstrated that blocking CXCL16 led to a reduction in liver inflammation and impaired infiltration and function of natural killer T (NKT) and natural killer (NK) cells. These findings suggest that CXCL16 is a promising non‐invasive biomarker of liver inflammation in CHB patients and may play a role in inducing liver inflammation via a NKT and NK cell pathway.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 36 references indexed in Scilit:
- A possible role for NKT-like cells in patients with chronic hepatitis B during telbivudine treatmentImmunology Letters, 2014
- Systematic review with meta‐analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosisAlimentary Pharmacology & Therapeutics, 2014
- Chemokine Receptor CXCR6-Dependent Hepatic NK T Cell Accumulation Promotes Inflammation and Liver FibrosisThe Journal of Immunology, 2013
- CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular CarcinomaCancer Research, 2012
- Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17Blood, 2012
- The CXCL16 A181V Mutation Selectively Inhibits Monocyte Adhesion to CXCR6 but Is Not Associated With Human Coronary Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Accelerated liver fibrosis in hepatitis B virus transgenic mice: Involvement of natural killer T cellsHepatology, 2010
- Enhanced Tumor Metastasis in Response to Blockade of the Chemokine Receptor CXCR6 Is Overcome by NKT Cell ActivationThe Journal of Immunology, 2009
- Intravascular Immune Surveillance by CXCR6+ NKT Cells Patrolling Liver SinusoidsPLOS Biology, 2005
- The Transmembrane CXC-Chemokine Ligand 16 Is Induced by IFN-γ and TNF-α and Shed by the Activity of the Disintegrin-Like Metalloproteinase ADAM10The Journal of Immunology, 2004